Andere Kunden interessierten sich auch für
![Therapeutic Proteins]( "Therapeutic Proteins")
Therapeutic Proteins75,99 €![Ethnopharmacology and Drug Discovery for COVID-19: Anti-SARS-CoV-2 Agents from Herbal Medicines and Natural Products]( "Ethnopharmacology and Drug Discovery for COVID-19: Anti-SARS-CoV-2 Agents from Herbal Medicines and Natural Products")
Ethnopharmacology and Drug Discovery for COVID-19: Anti-SARS-CoV-2 Agents from Herbal Medicines and Natural Products110,99 €![Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists]( "Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists")
Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists174,99 €![Proteomics for Drug Discovery]( "Proteomics for Drug Discovery")
Proteomics for Drug Discovery110,99 €![Systems Biology in Drug Discovery and Development]( "Systems Biology in Drug Discovery and Development")
Systems Biology in Drug Discovery and Development74,99 €![G Protein-Coupled Receptors in Drug Discovery]( "G Protein-Coupled Receptors in Drug Discovery")
G Protein-Coupled Receptors in Drug Discovery81,99 €![Drug Target Selection and Validation]( "Drug Target Selection and Validation")
Drug Target Selection and Validation103,99 €
This volume offers a broad and interdisciplinary view of modern approaches to drug discovery as used by pharmaceutical companies and research institutes. It comprehensively covers proteomics, bioinformatics, screening techniques such as high-throughput-, natural compounds-, and NMR-based-screenings, combinatorial chemistry, compound library design, ligand- and structure-based drug design and pharmacokinetic approaches. Each of the thirteen chapters reviews the theory, background and application of a key technology in drug discovery, complemented by an extensive list of references to the original literature. This concise source of information will be useful for researchers, both in industry and academia, as well as students in the fields of medicinal, pharmaceutical and computational chemistry, bioinformatics, biochemistry, molecular biology and pharmacology. Features and benefits - Structure-based drug design, molecular modeling, bioinformatics, screening methods, combinatorial chemistry and physicochemical concepts in drug discovery are comprehensively covered. - The volume is written from the viewpoint of the "drug researcher" working in the pharmaceutical industry, and also presents chapters on novel approaches developed in academia. - Offers high practical value for young scientists who need a quick introduction to the topic. - Provides an overview of the drug discovery process, particularly for specialized scientists working in drug discovery and pharma-managers.
Research in the pharmaceutical industry today is in many respects quite different from what it used to be only fifteen years ago. There have been dramatic changes in approaches for identifying new chemical entities with a desired biological activity. While chemical modification of existing leads was the most important approach in the 1970s and 1980s, high-throughput screening and structure-based design are now major players among a multitude of methods used in drug discov ery. Quite often, companies favor one of these relatively new approaches over the other, e.g., screening over rational design, or vice versa, but we believe that an intelligent and concerted use of several or all methods currently available to drug discovery will be more successful in the medium term. What has changed most significantly in the past few years is the time available for identifying new chemical entities. Because of the high costs of drug discovery projects, pressure for maximum success in the shortest possible time is higher than ever. In addition, the multidisciplinary character of the field is much more pronounced today than it used to be. As a consequence, researchers and project managers in the pharmaceutical industry should have a solid knowledge of the more important methods available to drug discovery, because it is the rapidly and intelligently combined use of these which will determine the success or failure of preclinical projects.
Research in the pharmaceutical industry today is in many respects quite different from what it used to be only fifteen years ago. There have been dramatic changes in approaches for identifying new chemical entities with a desired biological activity. While chemical modification of existing leads was the most important approach in the 1970s and 1980s, high-throughput screening and structure-based design are now major players among a multitude of methods used in drug discov ery. Quite often, companies favor one of these relatively new approaches over the other, e.g., screening over rational design, or vice versa, but we believe that an intelligent and concerted use of several or all methods currently available to drug discovery will be more successful in the medium term. What has changed most significantly in the past few years is the time available for identifying new chemical entities. Because of the high costs of drug discovery projects, pressure for maximum success in the shortest possible time is higher than ever. In addition, the multidisciplinary character of the field is much more pronounced today than it used to be. As a consequence, researchers and project managers in the pharmaceutical industry should have a solid knowledge of the more important methods available to drug discovery, because it is the rapidly and intelligently combined use of these which will determine the success or failure of preclinical projects.